Roche’s Vabysmo Chases Regeneron’s Eylea With New Pivotal Macular Edema Wins
Executive Summary
The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.
You may also be interested in...
Roche’s Vabysmo Grabs Top Growth Spot As Sales Decline
The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.
Vabysmo Is Bright Spot For Roche In Bumpy Q3
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.